Texas Permanent School Fund Corp Boosts Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Texas Permanent School Fund Corp raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,372 shares of the specialty pharmaceutical company’s stock after buying an additional 178 shares during the quarter. Texas Permanent School Fund Corp owned about 0.06% of ANI Pharmaceuticals worth $852,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after purchasing an additional 33,359 shares in the last quarter. Quest Partners LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth about $150,000. Rubric Capital Management LP raised its position in shares of ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after buying an additional 277,989 shares in the last quarter. CastleKnight Management LP bought a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $513,000. Finally, Ranger Investment Management L.P. lifted its holdings in shares of ANI Pharmaceuticals by 1.8% in the 4th quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock valued at $23,965,000 after acquiring an additional 7,769 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In other news, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the sale, the chief operating officer now owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the sale, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Muthusamy Shanmugam sold 14,257 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the transaction, the chief operating officer now directly owns 635,363 shares in the company, valued at approximately $40,129,527.08. The disclosure for this sale can be found here. Insiders have sold 46,007 shares of company stock worth $2,911,790 in the last three months. Corporate insiders own 12.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIP has been the topic of a number of recent research reports. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday. Truist Financial reiterated a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Finally, Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.80.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $59.66 on Friday. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The stock’s fifty day moving average is $61.07 and its two-hundred day moving average is $63.71. ANI Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $70.81. The company has a market capitalization of $1.25 billion, a PE ratio of 37.29 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. During the same period in the prior year, the business posted $1.06 earnings per share. The business’s revenue for the quarter was up 18.5% on a year-over-year basis. As a group, analysts expect that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.